Welcome to the Healthcare Revolution.
| Incubation & Joint Venture | Research & Commercialization | Comprehensive Research Provision |
Genoloam aims to become a forerunner in the new era of the healthcare industry.
We make continuous efforts to combine advanced medical technologies and non-medical fields ranging from Biotechnology to Information Technology and Artificial Intelligence in order to provide better Prevention, Diagnostics, Treatment and Care. Our comprehensive health solution service includes sales of innovative diagnostic reagents or examination devices in healthcare, and the management of most accurate screening equipment, reagents, and consumables. Over the years, GENOLOAM has established strong relationships with leading healthcare companies worldwide to support everyone’s exact health situation and needs. Explore our website to learn more about what we have to offer, and get in touch with any questions.
GENOLOAM IS HERE FOR YOU.
Genoloam Business Areas | Healthcare You Can Trust
Incubation & Joint Venture
The healthcare industry is going through digitalization at a rapid pace and these changes are altering existing methods and relations between providers and beneficiaries of various healthcare services. This change is both an opportunity and crisis for the service providers that make up the healthcare industry, while customers have more options to choose from among the variety of services. GENOLOAM is focusing on these market changes and aims to incubate digital healthcare services based on deep learning and artificial intelligence. The healthcare industry has just entered 4th industrial revolution, where position and status in the market share structure differs greatly depending on who provides customer-oriented & friendly services foremost. To be among the forerunners, GENOLOAM is actively conducting joint venture businesses by making full use of our IT & Hardware expertise and capabilities.
Research & Commercialization
After continuous analysis of current market problems, needs, and changes, GENOLOAM invests significant attention and time in finding companies and research institutes that innovate new technologies and meaningful research. We conduct joint research with leading technology development companies and research institutes with the aim to introduce excellent innovative technology and lead research into new markets. Furthermore, GENOLOAM supports various roles to ensure that new technologies can be implemented into new markets efficiently and generate profits smoothly.
Through these activities, GENOLOAM aims to produce value-added results by providing the best coordination between technology development institutions and local partners and creates a win-win situation through their respective roles.
Comprehensive Solution Provision
GENOLOAM has been making targeted efforts to provide more accurate and rapid measures in diagnosis fields such as molecular biology, genetics, and POC. Through close partnerships with leading healthcare companies, we will continue to find new and advanced reagents, instruments, and technologies, verify their performance & quality and achieve an absolute synergy between new technologies and the current industry developments.
Based on these efforts, knowledge, and accumulated network, GENOLOAM aims to provide a one-stop & comprehensive diagnosis solution for labs, hospitals and companies, enabling the highest level of performance and productivity.
Genoloam Activities | Revolutionizing the Healthcare Industry
-
![Genoloam Fimlab]()
Genoloam Enters Into Consulting Partnership With Fimlab OY
February 27, 2022
GENOLOAM is excited to begin collaboration with Fimlab Oy, one of the leading medical laboratory service providers in Finland and Nordic area, by providing consultation in the fields of healthcare, diagnostic services and management consulting. Together, we will aim to develop better healthcare services and help revolutionize healthcare industry.
-
![Genoloam EDGC]()
Genoloam Selected by EDGC as the Official Supervising Partner for Liquid Biopsy Research
February 15, 2022
EDGC is a world-class global healthcare company that develops leading-edge technology for genome sequencing through fusion of personal medical and genetic data. Their latest development in Liquid Biopsy for Early Diagnosis of Cancer, Monitoring Cancer, Companion Diagnostics and Organ Transplant Rejection Monitoring without the need for Tissue Biopsy is another successful step in the ultra-precision medicine field. -
![Genoloam Optolane]()
Optolane Acquires European CE-IVD Certification for 30-Minute Ultra-Fast PCR Diagnostic Device
January, 2022
GENOLOAM is proud to announce that our partner company, Optolane, a company specializing in semiconductor-based diagnostic products, has obtained European certification (CE-IVD) for two of its products: 1.) a gene amplification diagnostic (Real-Time PCR) product that produces the result from sample collection within 30 minutes and 2.) a PCR diagnostic device that can perform simultaneous testing.
-
![Genoloam BIO3S]()
Genoloam Enters Into Partnership With BIO3S and Becomes an Official Sales Partner in Europe
November 3, 2021
On the 3rd of November 2021, GENOLOAM and BIO3S held a signing ceremony in which GENOLOAM was appointed by BIO3S as official sales representative in Europe. BIO3S is a leading healthcare company in South Korea, and their latest innovation BeanGuard Gargle Technology was developed with the aim to ease and quicken the process of PCR testing for COVID-19.
Genoloam Portfolio | Carefully Curated for Your Healthy Future
-
![Genoloam Regikirona]()
REGKIRONA, MONOCLONAL ANTIBODY TREATMENT AGAINST COVID-19
GENOLOAM supplies Regkirona, a monoclonal antibody medicine, by CELLTRION HEALTHCARE CO., LTD. used for treating COVID-19 in adults who do not require supplemental oxygen and are at increased risk of their disease becoming severe. Regdanvimab has been designed to attach itself to the spike protein of SARS-CoV-2 consequently blocking cellular entry and SARS-CoV-2 infection. CELLTRION HEALTHCARE CO., LTD. has received drug approval authorization for Regkirona in South Korea and Europe, and for Emergency Use of Authorization (EUA) or Conditional Marketing Authorization (CMA) in Indonesia, Brazil, Peru and Australia.
Read more about neutralisation data against the Omnicron variant here.
-
![Genoloam V-Tube AB Medical]()
V-TUBE BLOOD COLLECTION TUBE
GENOLOAM supplies V-TUBE, Blood Collection Tube by AB MEDICAL, which has been fully verified in quality by leading university hospitals in South Korea and 10 countries around the world. V-TUBE is a disposable blood collection tube made of plastic with vacuum system to facilitate the predetermined draw volume of blood. V-TUBE contains additives designed to stabilize and preserve the specimen prior to analytical testing.
-
![Genoloam Optolane]()
COVID-19 RT PCR REAGENTS
GENOLOAM provides the world’s fastest and most accurate COVID-19 RT PCR reagents developed by 1DROP INC. 1copy™ Probe, one of 1drop's key technology, is a DNA-RNA hybrid probe that is used with a thermally stable enzyme, RnaseH, suitable for hot start technique to maximize the degradation efficiency. As a result, fluorescence emission is increased significantly which allows detection of DNA and RNA at the level of a single molecule.
-
![Genoloam Optolane]()
POCT / DIGITAL PCR
GENOLOAM supplies Onsite Real Time Service in collaboration with OPTOLANE, which is a Point of Care Service that allows PCR COVID19 inspection without the need for a full-scale lab. This service includes Digital PCR instrument the size of a lunch box with a sensitivity around 50 times higher as that of a RT-PCR. Higher sensitivity means that the instrument operates larger samples more effectively in terms of uniform mixing reagents, extraction of RNA/DNA and eventual detection of SARS-CoV-2. Therefore, the entire process is completed in about 65 minutes immediately after sample collection, and automatic reporting is completed online.
-
![Genoloam Genolution]()
RNA EXTRACTION SYSTEM
GENOLOAM supplies precision equipment and reagents for RNA extraction essential for all diagnostic tests, not just for detection of COVID-19. GENOLUTION Nextractor® NX-48S is an automated DNA/RNA isolation system that conducts rapid DNA/RNA isolation from a variety of samples using magnetic beads. The Automated Extractor saves time and effort by providing a platform and reagents capable of handling 48 samples per cycle in less than 20 minutes through quick and easy operation.
-
![Genoloam Next Generation Sequencing]()
HPV (HUMAN PAPILLOMAVIRUS)
In the current era of research on various methods for early detection, tracking, and observation of HPV (Human Papillomavirus), known as the main cause of cervical cancer, GENOLOAM provides an early detection and follow-up method for HPV using NGS (Next Generation Sequencing) as one of the more fundamental and convenient screening methods.
GENOLOAM, together with our leading healthcare partners in South Korea and the EU are currently developing Liquid Biopsy for early detection of cancer, NIPT (Non-Invasive Prenatal Test) for early diagnosis of fetuses and IT platforms based on telemedicine. These services are scheduled to be commercialized in early 2023.
Genoloam Partners | Trusted Network of Leading Professionals
Fimlab Laboratoriot Oy Ltd was established in 2011 and is one of the leading laboratory companies in Finland. Fimlab provides laboratory services, education and research in Pirkanmaa, Central Finland, Kanta-Häme, Ostrobothnia and Päijät-Häme regions and has comprehensive local network with leading university hospitals in Finland.
Established in 2012, AB Medical, Inc. is a leading company in the field of Medical supplies industry in South Korea, especially with the Blood Collection Tube, V-TUBE. V-TUBE™ with its own distinctive technologies with competitive price in the global market - South East Asia, Middle Asia, European countries, Africa and South America. There are three main factors that contribute to the superb quality of Evacuated Blood Collection Tube by AB Medical. The first factor is AB Medical’s own reagent technology that is proved to show clinically same function with BD Vacutainer™ by Chonnam National University Hwasun Hospital. Second is their high technology automatic facility with 6 patents that provide a precise quality with high speed - two workers can produce 12,000 tubes per 1 hour. And third is their reliable quality assurance system with related certificates - ISO13485, GMP, CE prove the product’s excellent quality.
EDGC is an international joint venture established in 2013 between EONE Laboratories and Diagnomics. EDGC has developed leading-edge technology for genome analysis through constant research and development and established a wide business network to expand its influence to the global market. As the global leader of genome business, EDGC has worked on global projects with the most influential BT and IT companies in the world such as Illumina and Microsoft. In addition, EDGC is participating as the only Asian partner of the Global Screening Array Consortium, in which only 12 other global leading companies participate in.
Celltrion Healthcare has become one of globally well-known bio pharmaceutical companies based in South Korea by developing biosimilars in a country with limited pharmaceutical resources and offering these biosimilars to patients around the world. Celltrion Healthcare, which has managed to pave new ways and create exciting achievements in the healthcare industry, will continue to produce a stable supply of products to bio pharmaceuticals in collaboration with its global partners and building its own distribution channels for pharmaceuticals.
Established in 2006, Genolution Inc. has been providing solutions toward a better life by focusing on fields of molecular diagnostics and RNAi. Their core technologies to develop faster, more affordable, and higher through-put nucleic acid extraction platforms led to the development of the Nextractor® nucleic acid extraction instrument series and extraction kits - they were vital for their progress in the fields of molecular diagnostics, genetic testing, and life sciences research. Moreover, Genolution's double-stranded RNA (dsRNA) synthesis technology enabled them to equip researchers with large-scale dsRNA for gene expression studies and pest control product development.
Optolane has developed a new diagnosis platform in response to the “sample-to-answer” of IVD (In-Vitro Diagnostics) market trends. Optolane’s core technologies are the integration of CMOS sensors with the fluorescent optical and thermal control systems in order to detect target genes and immunoassay diagnostic platform to the disease diagnosis and preventive home healthcare market. Our new diagnosis systems are small but simple, fast, and smart.
Founded in 2016, BIO3S has been committed to the research and development of products that can make people healthier. We have specialized in the research of viruses and developed a revolutionary virus handling technology called ViroGRIP. ViroGRIP enables encapsulating and neutralizing various types of viruses including Noro-Virus and COVID-19. ViroGRIP can be utilized in Daily Virus Protection products like hand sanitizer, hand soap, oral gargle or nasal wash. ViroGRIP can also support Next Generation Coronavirus Detection by effectively collecting virus in the saliva.
Founded in 2019, BigCare is a health management service platform that strives for people's happiness. The future of healthcare we pursue is embodied by our theme. With emerging technologies, BigCare predicts disease related risks, calming the fear and anxiety within people. They value people’s health-specific needs and deliver beyond their expectations. BigCare empowers people to take ownership of their own health data.